Unicycive Therapeutics (UNCY) Capital Expenditures (2022 - 2026)
Unicycive Therapeutics posted quarterly Capital Expenditures of $8000.0 for Q1 2026, down 50.0% year-on-year from $16000.0 in Q1 2025, and up 300.0% on a QoQ basis from $2000.0 in Q3 2025.
Unicycive Therapeutics (UNCY) has 4 years of Capital Expenditures data on file, last reported at $8000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 50.0% year-over-year to $8000.0; the trailing twelve-month figure through Mar 2026 stood at $16000.0 (down 80.49% YoY), and the FY2025 full-year result was $24000.0, down 66.67% from the prior year.
- Capital Expenditures for Q1 2026 stood at $8000.0, up from $2000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $24000.0 in Q3 2024 and bottomed at $2000.0 in Q1 2022.
- The 4-year median for Capital Expenditures is $8000.0 (2026), against an average of $11777.8.
- Peak annual rise in Capital Expenditures reached 166.67% in 2025, while the deepest fall reached 91.67% in 2025.
- A 4-year view of Capital Expenditures shows it stood at $2000.0 in 2022, then surged by 1000.0% to $22000.0 in 2024, then plunged by 90.91% to $2000.0 in 2025, then surged by 300.0% to $8000.0 in 2026.
- The last three Capital Expenditures figures came in at $8000.0 (Q1 2026), $2000.0 (Q3 2025), and $6000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |